Pandemic Disrupted Respiratory Syncytial Virus Season Timing

FRIDAY, April 7, 2023 (HealthDay News) – The typical timing of seasonal respiratory syncytial virus (RSV) epidemics (October to April) was disrupted during the COVID-19 pandemic, according to research published in the April 7 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Sarah Hamid, Ph.D., from the CDC in Atlanta, and colleagues characterized U.S. RSV seasonality during the prepandemic and pandemic periods using polymerase chain reaction test results reported to the National Respiratory and Enteric Virus Surveillance System (July 2017 to February 2023).
The researchers found that RSV circulation was historically low during the 2020 to 2021 season. During the 2021 to 2022 season, RSV began earlier and continued longer than during prepandemic seasons. A return toward prepandemic seasonality began in the 2022 to 2023 season, which started later than the 2021 to 2022 season but earlier than prepandemic seasons. In 2022 to 2023, RSV onset occurred in June and positive PCR results peaked in November. Compared with prepandemic seasons, the peak was higher (19 percent versus range of 13 to 16 percent) in the 2022 to 2023 surveillance year, with the epidemic lasting 32 weeks until the offset in January.
"In the United States, disruption of the seasonal circulation of RSV was observed during the COVID-19 pandemic as nonpharmaceutical interventions (e.g., school closures and masking) reduced respiratory virus transmission," the authors write. "Ongoing monitoring of RSV seasonality can guide the timing of immunoprophylaxis and evaluation of new immunization products. Although an eventual return to prepandemic RSV seasonality is expected, clinicians should be aware that off-season RSV circulation might continue."
Related Posts
Más de tres cuartas partes de los estadounidenses de a partir de 16 años han tenido COVID, según los CDC
MIÉRCOLES, 5 de julio de 2023 (HealthDay News) -- Aunque poco más de la mitad de...
Dapagliflozin Cuts CV Risk in Heart Failure With Preserved LVEF
MONDAY, Aug. 29, 2022 (HealthDay News) -- For patients with heart failure with...
Cognitive Impairment Predicts Outcomes for ICU Survivors
FRIDAY, July 1, 2022 (HealthDay News) -- For intensive care unit survivors,...
Cystatin C-Based Equation Accurate for Estimating Glomerular Filtration Rate
THURSDAY, Jan. 26, 2023 (HealthDay News) -- A cystatin C (cys)-based European...